Skip to main content Help with accessibility Skip to main navigation

Vedolizumab SC

Indication

Crohn's disease
Ulcerative colitis

Red

Brand:

Entyvio

Nice TA:

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Gastro-intestinal system

Background

Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.
Treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.

The patient and/or carer must receive adequate training in subcutaneous injection technique if their specialist determines that it is appropriate to self-inject and with medical follow-up as necessary. Suitability of the patient for subcutaneous home use should be assessed and patients should be advised to inform their healthcare professional if they experience symptoms of an allergic reaction before administering the next dose. Patients should seek immediate medical attention if developing symptoms of serious allergic reactions.

 

Also approved for S.C use - see https://www.lancsmmg.nhs.uk/medicines-library/vedolizumab-nice-ta-352/

https://www.lancsmmg.nhs.uk/medicines-library/vedolizumab-nice-ta342/

 

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 18 - Oct - 2022